Tehran – An international online seminar titled “Toxic Animals and Anti-toxicity: Bridging Science, Innovation, Global Health” at the Razi Vaccine and Serum Institute in Tehran on February 17th and 18th.
With support from the World Health Organization (WHO), the event is intended to be introduced by the Institute as a manufacturing science fiction hub for anti-venoms in the region. The Institute not only exports anti-berrym, but also allows technology to be transferred to other countries, reported by the Mehr News agency.
The event brought together many notable researchers from various countries, including Brazil, Thailand, the UK, Costa Rica, Nepal and Oman.
This seminar will serve as a platform for introducing the country’s scientific capabilities and developing scientific interactions and collaborations with trusted global centres.
It covers a variety of topics, including the mechanisms of the action of venom, epidemiology of toxic bites, innovation in anti-venom research, emergency treatment of hospital victims, and innovative technologies for anti-venom development.
Among other main goals is to reduce production costs in developing countries, characterized by anti-venoms produced by the Razi Institute and compare them with those made abroad.
In contrast to those made in other countries, domestically produced antivenoms retain many benefits, such as being multivalent (multiple) and being able to neutralize poisons.
These features make many countries interested in working with the Razi Institute to manufacture anti-toxicity.
Razi Institute
Founded on January 6, 1925, Razi Institute has become a pioneer in Iran’s vaccine and serum production in response to the devastating Rinderpest Pandemic. Today, we offer a diverse portfolio of over 80 biological products, reflecting years of dedicated research and innovation by scientists.
The Razi Vaccine and Serum Institute operates six branches in Iran in Mashhad, Ahvaz, Shiraz, Karman, Maland and Arak.
During the Covid-19 pandemic, the second Iranian vaccine for the coronavirus, Razi Cov Pars, was developed by the Razi Vaccine and Serum Institute.
The vaccine is protein-based and uses recombinant versions of the spike protein and uses the immune system against the virus as a tutor by producing antibodies.
It has been developed in three sessions. The first two doses are injectable and the third dose is intranasal. The second dose of the vaccine is injected into the volunteers 21 days later, and the third dose is inhaled 51 days later.
The method applied to the production of this vaccine is in accordance with World Health Organization (WHO) regulations.
The laboratory began work on the vaccine in February 2020, and after the early stages it passed the animal testing phase in April 2020. Immunization occurred for 8-9 months.
Cov-Pars was developed under the guidance of the Iranian Ministry of Health and Food and Drug Agency expertise.
At the end of the second phase of the clinical trial, Cov Pars proved 80% of immunogenicity.
Many countries are requesting that they purchase Iranian-made Cov Pars vaccines for Covid-19.
The Institute (also associated with the Ministry of Agriculture) was able to produce 20 million doses of vaccines by the end of 2021.
The Razi Vaccine and Serum Production Institute celebrated its 100th anniversary on Sunday, January 5th, 2025 with a high-level ceremony in Tehran.
mt/mg